Trends and disparities in cardiovascular disease–related mortality among adults with myeloproliferative neoplasms in USA
Our findings indicate a significant decline with notable gender, racial/ethnic, and regional differences in CVD-related mortality among patients with MPN over the past two decades. We emphasize the importance of a collaborative approach between oncologists and cardiologists in managing these patients, highlighting the potential benefits of integrating cardio-oncology services to enhance patient outcomes.
Authors
- Zain Ul Abideen Asad (ORCID: https://orcid.org/0000-0003-3110-7049)
- Ana Barac (ORCID: https://orcid.org/0000-0002-9935-8904)
- Taha Al‐Juhaishi
- Avirup Guha (ORCID: https://orcid.org/0000-0003-0253-1174)
- Muhammad Shahzeb Khan (ORCID: https://orcid.org/0000-0003-1250-6351)
- Siddharth Agarwal (ORCID: https://orcid.org/0000-0002-5581-5464)
- Eric H. Yang (ORCID: https://orcid.org/0000-0003-4889-7454)
- Abdul Rafeh Naqash (ORCID: https://orcid.org/0000-0001-7622-720X)
- Usama Qamar (ORCID: https://orcid.org/0009-0005-1727-6411)
Institutions
- King Edward Medical University (PK)
- University of California, Los Angeles (US)
- Duke University (US)
- Augusta University (US)
- Mayo Clinic in Arizona (US)
- University of Oklahoma Health Sciences Center (US)
Publication Details
- Journal
- European Heart Journal Open
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1093/ehjopen/oeae101
- Citations
- 1
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.44
Funders
- U.S. Department of Defense
- American Heart Association
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- CSL Behring
- DOD Prostate Cancer Research Program